AVANOS MEDICAL, INC.
avanos.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2026 10-Q, filed May 5, 2026. Its latest SEC filing is a 15-12G from Aug 6, 2026.
10-Q for Q1 FY2026, filed May 5, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Sells enteral feeding and neonatal-care devices, as well as pain-management and recovery products, to hospitals and other healthcare providers.
10-K for FY2025, filed Feb 24, 2026We conduct our business in two operating and reportable segments that provide our medical device products to healthcare providers and…View ↗
Specialty Nutrition Systems (“SNS”) is a portfolio of products including:View ↗
Enteral feeding, which includes products such as our MIC-KEY® enteral feeding tubes and Corpak® patient feeding solutions. In the years…View ↗
Pain Management and Recovery (“PM&R”) is a portfolio of non-opioid pain solutions including:View ↗
Surgical pain and recovery products, such as our ON-Q® and ambIT® surgical pain pumps and our Game Ready® cold and compression therapy…View ↗
We direct our primary sales and marketing efforts toward hospitals, ambulatory care centers, and other sites of care. We engage with…View ↗
How Did They Make Money?
Customers buy feeding, neonatal-care, pain and recovery devices; Avanos bills when products ship or are delivered, with invoices typically due within 30 days.
10-K for FY2025, filed Feb 24, 2026Sales revenue is recognized at the time of product shipment or delivery of our products to unaffiliated customers, depending on shipping…View ↗
We provide medical products to distributors or end-user customers under supply agreements under which customers may place purchase orders…View ↗
Under our contracts with customers, our performance obligations are normally limited to shipment or delivery of products to a customer upon…View ↗
Amounts billed are typically due within 30 days, with a 1% discount allowed for distributors if payments are made within 15 days. We…View ↗
-
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by product or service ↗
$701.2M
-
10-K for FY2025, filed Feb 24, 2026
$701.2M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Total Specialty Nutrition Systems
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
62% |
Total Specialty Nutrition Systems, FY2025
$432.9M Sources
|
Sold outright |
|
Total Pain Management and Recovery
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
34%
FY2022: 50%
|
Total Pain Management and Recovery, FY2025
$237.8M Sources
|
Sold outright |
|
Corporate and Other
|
4.4% |
Corporate and Other, FY2025
$30.5M Sources
|
Who Were Their Customers?
Avanos markets mainly to hospitals, ambulatory care centers and other care sites, but generally sells through wholesale distributors; it also sells directly to some healthcare facilities and end users. Outside North America, sales may be direct or through distributors.
10-K for FY2025, filed Feb 24, 2026We direct our primary sales and marketing efforts toward hospitals, ambulatory care centers, and other sites of care. We engage with…View ↗
While our products are generally marketed directly to hospitals and other healthcare providers, they are generally sold through third-party…View ↗
Outside North America, sales are made either directly to end-user customers or through distributors, depending on the market served. In the…View ↗
Did Revenues Turn Into Profits?
Not on paper. It lost $72.9M in FY2025, but brought in more cash than it spent: $43.1M of free cash flow.
10-K for FY2025, filed Feb 24, 2026
−$61.6MView ↗
10-K for FY2025, filed Feb 24, 2026
−$72.9MView ↗
10-K for FY2025, filed Feb 24, 2026
$43.1MView ↗
How Were They Changing?
10-Q for Q1 FY2026, filed May 5, 2026
Open tableView ↗
-
Jul 30, 2026
AIP completed its acquisition of Avanos
Avanos became a private company, and its common stock ceased trading on the New York Stock Exchange.
Sources
8-K, filed Jul 30, 2026
American Industrial Partners Completes Acquisition of Avanos Medical, Inc.View ↗
Grew. Revenue grew 19% in 4 years, from $587M in FY2021 to $701.2M in FY2025, about 5% a year.
Portfolio refocus
The earlier portfolio included respiratory health products alongside digestive and pain products; the latest report centers the business on specialty nutrition and pain management and recovery after the respiratory health business sale.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 24, 2026We conduct our business in one operating and reportable segment that provides our medical device products to healthcare providers and…View ↗
Digestive health products such as our MIC-KEY enteral feeding tubes, Corpak patient feeding solutions and NeoMed neonatal and pediatric…View ↗
Acute pain products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems. In the year ended…View ↗
Vascular access addition
The latest portfolio includes Nexus products in vascular access, expanding beyond the digestive and pain offerings described in the earlier report.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 24, 2026
Who Did They Compete With?
Competes with Boston Scientific, Cook Medical, Applied Medical Technology, Cardinal Health, Pacira Pharmaceuticals, Stryker, Medtronic, Pajunk Medical Systems, Stratus Medical, and Nice Recovery Systems
10-K for FY2025, filed Feb 24, 2026Specialty Nutrition Systems: Boston Scientific Corporation, Cook Medical, Applied Medical Technology, Inc. and Cardinal Health Pain…View ↗
Loading...
